Consensus statement on the use of gonadotropin-releasing hormone analogs in children
Department of Pediatrics; Department of Cell Biology
Medical Subject Headings
Adolescent; Body Height; Bone Density; Child; Female; Gonadotropin-Releasing Hormone; Humans; Hypothyroidism; Luteinizing Hormone; Nafarelin; Organ Size; Ovary; Polycystic Ovary Syndrome; Puberty, Precocious; Uterus
OBJECTIVE: Gonadotropin-releasing hormone analogs revolutionized the treatment of central precocious puberty. However, questions remain regarding their optimal use in central precocious puberty and other conditions. The Lawson Wilkins Pediatric Endocrine Society and the European Society for Pediatric Endocrinology convened a consensus conference to review the clinical use of gonadotropin-releasing hormone analogs in children and adolescents.
PARTICIPANTS: When selecting the 30 participants, consideration was given to equal representation from North America (United States and Canada) and Europe, an equal male/female ratio, and a balanced spectrum of professional seniority and expertise.
EVIDENCE: Preference was given to articles written in English with long-term outcome data. The US Public Health grading system was used to grade evidence and rate the strength of conclusions. When evidence was insufficient, conclusions were based on expert opinion.
CONSENSUS PROCESS: Participants were put into working groups with assigned topics and specific questions. Written materials were prepared and distributed before the conference, revised on the basis of input during the meeting, and presented to the full assembly for final review. If consensus could not be reached, conclusions were based on majority vote. All participants approved the final statement.
CONCLUSIONS: The efficacy of gonadotropin-releasing hormone analogs in increasing adult height is undisputed only in early-onset (girls <6 years>old) central precocious puberty. Other key areas, such as the psychosocial effects of central precocious puberty and their alteration by gonadotropin-releasing hormone analogs, need additional study. Few controlled prospective studies have been performed with gonadotropin-releasing hormone analogs in children, and many conclusions rely in part on collective expert opinion. The conference did not endorse commonly voiced concerns regarding the use of gonadotropin-releasing hormone analogs, such as promotion of weight gain or long-term diminution of bone mineral density. Use of gonadotropin-releasing hormone analogs for conditions other than central precocious puberty requires additional investigation and cannot be suggested routinely.
Rights and Permissions
Citation: Pediatrics. 2009 Apr;123(4):e752-62. Epub 2009 Mar 30. Link to article on publisher's site
Carel, Jean-Claude; Eugster, Erica A.; Rogol, Alan; Ghizzoni, Lucia; Palmert, Mark R.; Lee, Mary M.; and ESPE-LWPES GnRH Analogs Consensus Conference Group, "Consensus statement on the use of gonadotropin-releasing hormone analogs in children" (2009). Lee Lab. 9.